logo
Plus   Neg
Share
Email

Teva And Regeneron Announce Positive Phase 3 Fasinumab Results

Teva Pharmaceutical Industries Ltd. (TEVA) and Regeneron Pharmaceuticals Inc. (REGN) announced positive topline results from a Phase 3, randomized, double-blind, placebo-controlled study of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip. At the week 16 primary efficacy analysis, the study met both co-primary endpoints and all key secondary endpoints.

Fasinumab-treated patients experienced significantly less pain and significantly improved functional ability from baseline compared to placebo.

Interim safety data indicate that fasinumab was generally well tolerated, with similar adverse events (AEs) as those observed in previous fasinumab trials. At week 16, treatment discontinuations due to AEs had occurred in 6% of the placebo group patients, 5% of the fasinumab 1 mg every eight weeks group patients and 6% of the fasinumab 1 mg every four weeks group patients.

The fasinumab safety program was designed to capture all arthropathies (joint damage), including those identified due to symptoms and those identified by regularly-scheduled radiographic monitoring, the first of which was scheduled at week 24. Among the approximately 65% of patients who had completed their first radiographic assessment, the placebo-adjusted rate of adjudicated arthropathies was approximately 2%.

The majority of arthropathies were captured by the regularly-scheduled radiographic monitoring and involved isolated joint space narrowing, called RPOA-1 (rapid progressive OA type 1). No cases of osteonecrosis have been identified to date in this study.

The companies plan to present detailed results at an upcoming medical congress.

Regeneron and Teva are jointly developing fasinumab as part of a global collaboration agreement. In Japan and 10 other Asian countries, Mitsubishi Tanabe Pharma Corporation holds exclusive development and commercial rights for fasinumab.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google announced a new $600 million investment for the expansion of Mayes County data center. The tech giant had started the data center in 2007 and expanded three times already. The new investment will add 100 jobs to Pryor community, Google CEO Sundar Pichai said during the announcement. In... King Arthur Flour, Inc. voluntarily recalled certain lots of 5 lb. Unbleached All-Purpose Flour due to the potential presence of Escherichia coli bacteria (E. coli), The U.S. Food and Drug Administration (FDA) stated. The company announced it is recalling 14,218 cases of the potentially affected lots that were distributed through retailers and distributors nationwide. Burger King has launched a new Upside Down Whopper in celebration of the third season of Netflix series "Stranger Things." The hamburger chain, in partnership with Netflix, announced it will start selling an Upside Down Whopper sandwich, which is just a regular Whopper served upside down, from June...
Follow RTT